Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cempra’s Antibiotic Drug Close To Receiving FDA Approval

XTALKS VITALS NEWS

FDA

Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin.

Share this!

November 8, 2016 | by Sarah Hand, M.Sc.

An independent advisory panel to the US Food and Drug Administration (FDA), has voted 7-6 that the regulatory agency should approve Cempra’s antibiotic drug, solithromycin. The close vote found that solithromycin’s ability to combat community-acquired bacterial pneumonia (CABP) outweighed its potential risks.

While the drug showed efficacy across multiple clinical trials, the committee was concerned about the drug’s potentially negative effects on the liver. The FDA advisory committee concluded that Cempra had failed to provide sufficient safety data on solithromycin, in order to fully assess its risks.

“We appreciate the meaningful discussion from today’s panel,” said Dr. Prabhavathi Fernandes, president and CEO of Cempra. “Their supportive view and thoughtful comments on approaches to ensuring appropriate use are consistent with Cempra’s commitment to make solithromycin available to the right patients for a five to seven day course of an oral and/or IV macrolide as monotherapy for CABP.”



Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin. Though the FDA often does follow the guidance of the independent advisory panel, it is not obligated to do so.

“Antibiotic resistance is reaching alarming rates across the globe,” said Fernandes. “In the U.S. alone, pneumonia is the leading cause of death due to infectious disease and rates of pneumococcal resistance to current macrolides for the treatment of CABP can exceed 50 percent. We believe solithromycin has the potential to offer patients and physicians an important new treatment option and we look forward to continuing to work with the FDA as it completes its review.”

If solithromycin gains regulatory approval, it will be the first new macrolide antibiotic with both an oral and an IV formulation in more than 20 years. Cempra is also awaiting an approval decision by the European Medicines Agency (EMA).


Keywords: Antibiotic, FDA, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.